Johnson & Johnson (JNJ)
Johnson & Johnson - FDA approves label expansion, cementingTREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Johnson & Johnson - FDA approves label expansion, cementingTREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Essential Performance and Real-time Control Without the Baggage
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
SLB e Vår Energi ampliano la collaborazione digitale per ridimensionare la pianificazione dello sviluppo integrato di pozzi e giacimenti
Pfizer Inc. - Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
SLB und Vår Energi weiten ihre digitale Zusammenarbeit aus, um die Bohrloch- und integrierte Feldentwicklungsplanung zu optimieren
INVESTOR ALERT: Securities Class Action Filed Against Calix, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
VERRA MOBILITY CORPORATION INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
CTEV INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Claritev Corporation